Insulin glargine biosimilar - Xentria
Alternative Names: NKF-INS Glargine; NKF-INS Glargine (G); NKF-INS(G)Latest Information Update: 03 Feb 2025
Price :
$50 *
At a glance
- Originator Xentria
- Class Antihyperglycaemics; Insulins; Pancreatic hormones
- Mechanism of Action Insulin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Diabetes mellitus
Most Recent Events
- 29 Oct 2024 Phase-I clinical trials in Diabetes mellitus (In volunteers) in South Africa (SC) (NCT06627478)
- 04 Oct 2024 Preclinical trials in Diabetes mellitus in USA (SC) before October 2024 (Xentria pipeline, October 2024)
- 04 Oct 2024 Xentria plans a phase I pharmacokinetics/pharmacodynamics trial (In volunteers) (SC, Injection) in October 2024 (NCT06627478)